There is evidence to suggest that SGLT-2 inhibitors can prevent heart failure (HF) in patients with T2DM and decrease major adverse cardiovascular events and hospitalization for HF in patients with concomitant HF and T2DM [59,60]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.